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Introduction
 Breast cancer (BC) is the most frequent cancer among 
Iranian women, comprising 23.6% of all recorded cases 
of cancer (Cancer office of center for disease control and 
prevention, 2007; Sadjadi et al., 2009). Based on (Harirchi 
et al., 2004), BC in Iranian women occurs 10 years earlier 
compared to those living in developed countries. Although 
adjuvant chemotherapy treatments after surgery are 
among the options women with breast cancer have, the 
number of studies conducted in Iran in order to determine 
the appropriate adjuvant therapy is still scarce (Fazl-Ali 
Zadeh and Hatami, 2004; Bakhtyari and Hajyan, 2007; 
Kadivar and Bozorgmehr 2007). Moreover, the optimal 
type of adjuvant chemotherapy is still a matter of debate 
(Cocconi et al., 2004; Hayes, 2009). Whatever the case, 
however, adjuvant chemotherapy is believed to increase 
disease-free survival (DFS) and overall survival (OS) 
following surgery for BC patients (Early Breast Cancer 
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Abstract
  Objective: The main objective of the present study was to compare the effects of three common chemotherapy 
regimes in terms of disease-free survival (DFS) of breast cancer (BC) patients; the three explored regimes were 
taxane-based, anthracycline-based and CMF (cyclophosphamide methotrexate and 5-fluorouracil). Materials 
and methods: In this historical-cohort study, we obtained the information of 62 patients with confirmed BC in 
non-metastatic stage and followed them for 8 years. All the patients had undergone modified radical mastectomy 
surgery and had received adjuvant chemotherapy in three medical centers in Tehran, Iran. DFS was considered 
as the end-point. Afterwards, an extended log-logistic regression model was used to compare these regimes. 
Results: The mean (SD) age of patients was 49.0 (10.3) years. The median time of follow-up was 20.0 months and 
the probability of 5-years DFS was 0.48. Survival analysis indicated that the type of chemotherapy (OR(CMF 
vs. taxane) = 0.33, OR(anthracycline vs. taxane) = 0.74), grade (OR(III vs. I or II) = 0.35), tumor size (OR(>5cm 
vs. <5cm)= 0.179) and nodal involvements (OR(Yes vs. No)= 0.36) affected DFS. Conclusion: The current study 
revealed that the efficacy of taxane-based, in terms of DFS, was more than CMF (p = 0.05). Moreover, taxane-based 
chemotherapy prolonged DFS more than anthracycline-based one although the difference was not significant 
(p= 0.63). Finally, considering the importance of tumor size, histological grade and number of involved lymph 
nodes in lengthening DFS, it is crucial to highlight the role of public education and screening programs in order 
to detect tumor in its early stages.
Keywords:  Survival analysis - breast neoplasms - adjuvant chemotherapy - disease-free survival
Trialist Collaborative Group, 1992). 
 Montemurro and Aglietta (2009) summarized over 
three decades of adjuvant chemotherapy for BC patients 
into three eras: first, the era of CMF regime; then, that 
of anthracyclines; and more recently taxanes. CMF has 
been a standard regime in Europe since the middle 1970s 
(Bonadonna et al., 1976). anthracyclines play an important 
role in adjuvant/neoadjuvant settings. anthracyclines-
based chemotherapy proved to be, at least, as effective 
as CMF (Martin et al., 2003).
 National adjuvant breast and bowel project (NASBP) 
B28 study showed that taxane-based (paclitaxel after 
doxorubicin plus cyclophosphamide) regime was more 
effective compared to anthracycline-based (doxorubicin 
plus cyclophosphamide) one in an adjuvant setting in terms 
of DFS and OS (overall survival). This advantage of the 
former regime was notably related to lymph node positive 
patients. Nevertheless, the results were much more limited 
for positive hormone-receptor patients (Mamounas et 
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al., 2005). Inasmuch as controversial results have been 
reported regarding the role of adjuvant chemotherapy in 
positive estrogen receptor (ER) patients (Montemurro 
and Aglietta, 2009), using complex statistical models to 
determine the role of  ER in the recurrence risk has been 
recommended instead (Dignam et al., 2009). 
 In this study, we compared the effect of CMF, 
anthracycline-based and taxane-based regimes in adjuvant 
settings after modified radical mastectomy (MRM) 
surgery in terms of DFS. In so doing and to overcome 
the complexity related to the effect of ER status, we 
applied an extended parametric survival model with 
logistic distribution for logarithm of DFS. It should be 
mentioned that all the comparisons were adjusted by the 
tumor size, histological grade, lymph node involvement 
and ER status. 
Materials and Methods
Patients and setting:
 The data for this historical cohort study were obtained 
from three centers (hospitals of Shohadaye Tajrish, 
Madaen and Shahid Fayyazbakhsh) in Tehran, Iran. All 
adjuvant chemotherapy conducted in these centers from 
April 1997 to April 2005 was identified. We constrained 
our attention to BC women (i) who had undergone 
modified radical mastectomy (MRM) surgery, (ii) with 
no metastasis at the time of surgery and (iii) who had 
undertaken adjuvant chemotherapy for the first time using 
either CMF, anthracycline-based or taxane-based regimes 
(as elaborated on in the next subsection). Patients with 
poor quality data were eliminated from the study. Sixty 
two patients met these criteria and were included in the 
subsequent phases of this study.
Treatment regimes:
 The three arms of adjuvant chemotherapy were: 1- 
CMF regime: contains cyclophosphamide (600 mg/m2), 
methotrexate (40 mg/m2) and 5-fluorouracil (600 mg/m2) 
repeated every three weeks × 8 cycles; 2- anthracycline-
based regimes: combination chemotherapy regimes 
containing either (i) doxorubicin plus cyclophosphamide 
(AC) (60/600 mg/m2) repeated every three weeks × 
4 cycles or (ii) 5-fluorouracil (500 mg/m2) plus AC 
(50/500 mg/m2) repeated every three weeks × 6 cycles; 
3- taxane-based regimes: combination chemotherapy 
regimes contain a taxane agent. This can be either (i) AC 
(60/600 mg/m2) repeated every three weeks × 4 followed 
by paclitaxel (175 mg/m2) repeated every three weeks × 
4 cycles or (ii) AC (60/600mg/m2) repeated every three 
weeks × 4 followed by docetaxel (75-100 mg/m2) repeated 
every three weeks × 4 cycles. Tamoxifen, in a dosage of 20 
mg each day, was orally given to all positive ER patients 
after chemotherapy.
Determination, follow-up and diagnosis:
 Tumor characteristics such as node statues, tumor size, 
histological grade, status of ER and some risk factors of 
BC were recorded. Tumors were classified according to 
the tumor-node-metastasis (TNM) system of the American 
Joint Committee on Cancer (American Joint Committee 
on Cancer: AJCC 2002, 2002) and Scarff-Bloom-
Richardson was used as the grading system (Le Doussal et 
al., 1989). ER was determined by immunohistochemistry 
(IHC) method. Our patients were followed up by regular 
clinical examinations, laboratory profiles, serologic 
markers (CEA, CA15-3) and imaging evaluations. We 
recorded the number of days from surgery to the first 
recurrence/metastasis. The endpoint determined by biopsy, 
chest X-ray, ultrasound, bone scan, liver sonography and 
marker rising with physician confirmation. Most of the 
missing subjects were reached one way or another, mainly 
through phone calls. 
Statistical analysis:
 In this three-arm study, we used an extended parametric 
survival model to compare taxane-based with CMF and 
anthracycline-based regimes adjusted on some prognosis 
factors. (Royston, 2001) used log-normal as the suitable 
model for relapse time of patients with BC and ovarian 
cancer. It is equivalent to using a normal distribution for 
logarithm of the survival time. Hazard function of log-
normal distribution can decrease over time or initially 
increase to a peak and then decrease (Kalbfleisch and 
Prentice, 2002; Kleinbaum and Klein, 2005). Royston 
(2001) suggested using an extended survival model instead 
of a simple one. In the context of his studies, Browne 
(1998) and Browne (2006) utilize extended parametric 
model with complex parameters. In the current study, we 
used an extended parametric survival model in which we 
considered the logistic distribution for logarithm of DFS. 
While log-normal and log-logistic distributions are similar, 
the former has the advantage of being a proportional odds 
model (Klein and Moeschberger, 1997). In our log-logistic 
distribution, we considered the location parameter as a 
function of the tumor size (divided into two categories: 
less than or equal to 5 cm as reference category and more 
than 5 cm), histological grade (divided into two categories: 
well or moderately differentiated as reference category 
and non-differentiated) and involvement of lymph node 
(divided into two categories: positive as reference category 
and negative). In addition, we considered the scale 
parameter as a function of ER status (divided into two 
categories: negative as reference category and positive). 
In the ordinary log-logistic model, if patient exposed to a 
certain factor, odds ratio (OR) of recurrence  is constant 
over the time; nonetheless, it is a function of time in 
the extended log-logistic model (Kleinbaum and Klein, 
2005). This property of extended log-logistic model may 
overcome the difficulty in ER status (Dignam et al., 2009, 
Montemurro and Aglietta, 2009). In order to determine the 
appropriateness of the model and covariates that affected 
on the shape parameters, we used graphical method 
(Kleinbaum and Klein, 2005). 
 Furthermore, using Akaike information criterion 
(AIC), comparisons were made between the final extended 
model and two other models (Klein and Moeschberger, 
1997). The first model was a simple parametric survival 
model whose scale was constant, and we used ER in its 
location parameter. The second model was an extended 
parametric survival model with ER used in both location 
and scale parameters. An appropriate model can be 
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selected based on minimum value of AIC (Klein and 
Moeschberger, 1997). The software we used to analyze the 
database was R, Version 2.10.0, which is a programming 
environment for data analysis and graphics (available free 
from http://cran.um.ac.ir/bin/windows/contrib/)
Results
 The mean (SD) and median of follow-up time 
after MRM surgery were 26.7 (3.2) and 20.0 months, 
respectively (ranging from less than a month to 14.7 
years). At the end of the study, 67.7% of women had no 
recurrence or metastasis.
 The mean (SD) age of women was 49.0 (10.3), ranging 
from 26 to 73 years. While we observed a tendency to 
give taxane-based regimes to women with mean (SD) 
age 46.7(9.7), anthracycline-based to those with mean 
(SD) age 47.6 (10.7) and CMF regimes to those with 
mean (SD) age 54.0 (9.1), it was found that these age 
differences were not statistically significant (p = 0.09) 
(Table 1). The total mean (SD) of menarche age was 
13.5 (1.5). There were no significant difference among 
the age of menarche in different adjuvant chemotherapy 
arms (p = 0.6). Menopause women constituted 50.8% 
of all the patients in the current study. At the start of the 
study, the frequency of menopause and non-menopause 
women was similar (Table1). In addition, there was no 
significance difference among three arms with respect to 
the menopause status (p = 0.48). Women who received 
CMF had had more pregnancies than women in other 
adjuvant chemotherapy arms (p = 0.01).
 Table 2 illustrates that about 44% of the women were 
treated by anthracycline-based regime after surgery and 
around a quarter of patients (25.8%) were treated using 
CMF. Most of the patients were detected with a grade III 
tumor (40.4%) and only 15.5% of patients were detected 
Table 1. Risk Factors of Breast Cancer by the Type of Adjuvant Chemotherapy Regime
Risk factor  taxane-based CMF-based anthracycline-based Total
  Mean(SD) Mean(SD) Mean(SD) Mean(SD)
Age  46.7 (9.7) 54.0 (9.1) 47.6 (10.7) 49.0 (10.3)
Menarche age  13.7 (1.3) 13.5 (0.9) 13.4  (1.0) 13.5  (1.5)
No. of pregnancies    3.2 (1.8)   4.7 (2.4)   2.2  (1.7)   3.1  (2.1)
  N (%) N (%) N (%) N (%)
Menopause YES   8  (42.1) 10  (62.5) 13  (50.0) 31  (50.8)
 NO 11  (57.9)   6  (37.5) 13  (50.0) 30  (49.2)
 Total 19 (100.0) 16 (100.0) 26 (100.0) 61 (100.0)
Table 2. Major Characteristics of Patients and their Tumors
parameter     N (%)
adjuvant chemotherapy regime taxane-based regime 19 (30.6)
 anthracycline-based regime 27 (43.6)
 CMF regime 16 (25.8) 
Histological grade Well differentiated (I) 10 (21.3)
 Moderately differentiated (II) 18 (38.3)
 Non-differentiated (III) 19 (40.4) 
Involved  Lymph node Negative 21 (33.9)
 1-3 16 (25.8)
 4-10 14 (22.6)
 > 10 11 (17.7)  
Tumor size < 2   9 (15.5)
 2-5 34 (58.6)
 > 5 15 (25.9)  
ER status Negative 17 (28.8)
 Positive 42 (71.2)
Table 3. Estimation of Coefficients of Extended Log-logistic Model for Disease-free Survival
 Parameter   Coefficient (SE) p-value OR ( 95% CI)
Location  constant  9.04 (0.95) < 0.01 -
parameter Type of Adjuvant  taxane-based Reference - -
 Chemotherapy regime anthracycline-based -0.29 (0.60) 0.63 0.74 (0.23-2.43)
  CMF -1.11 (0.57) 0.05 0.33 (0.11-1.00)
 Histological grade I or II Reference - -
  III -1.04 (0.39) < 0.01 0.35 (0.16-0.76) 
 Tumor size  ≤5 cm Reference  -
  >5 cm -1.25 (0.47) < 0.01 0.29 (0.11-0.72) 
 Lymph node  No Reference  -
 involvement Yes -1.01 (0.56) 0.07 0.36 (0.12-1.09) 
Scale constant  0.00 (0.43) 0.99 -
parameter ER status Negative Reference  -
  Positive -1.06 (0.58) 0.05 -
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with a tumor size less than 2 cm. At the time of surgery, 
more than 40% of women had less than four positive 
lymph nodes.
 As mentioned before, we used an extended log-logistic 
model to compare the three chemotherapy regimes and 
compared it with two other models using AIC. The AIC 
of the simple parametric survival model (the first model), 
whose scale is constant and in which ER is used in location 
parameter, was 46.6. In the complex parameter model (the 
second model), in which ER is used in both location and 
scale parameters, AIC was 41.59. AIC of our model was 
smaller in comparison to the first and second models (AIC 
= 41.29); therefore, it seems to fit better. 
 Table 3 illustrates the estimation of parameters of 
extended log-logistic model. The results show that taxane-
based regime is significantly more efficient than CMF (p 
= 0.05) in terms of DFS. In addition, the effect of taxane-
based regime is more prominent than anthracycline-based 
regime although it is not significant (p = 0.63). 
 The extended log-logistic model indicates that the 
odds of recurrence or metastasis in women with a grade 
III tumor is 0.35 compared to the women with a grade I 
or II tumor (p < 0.01). A tumor of bigger size (> 5cm) 
results in poorer prognosis in comparison to smaller tumor 
(< 5cm) (odds ratio (OR) = 0.29; p < 0.01). Although not 
significant (p = 0.07), DFS in patients with positive lymph 
nodes is less than patients with negative lymph nodes. The 
ER status also has impact on the scale parameter of (log) 
DFS (p = 0.05) (Table 3). A negative coefficient for ER 
status indicated that ER-positive women who were treated 
with tamoxifen had better prognoses initially, compared 
to ER-negative women. However, tamoxifen effect was 
gradually reversed over time.
 Table 4 reveals the DFS percentage of high-risk (tumor 
size > 5cm, Grade III tumor and positive lymph node 
involvement) and low-risk (tumor size < 5cm, Grade 
I or II tumor and negative lymph node involvement) 
women based on their ER status and the type of adjuvant 
chemotherapy regimes. All relevant percentages, as can 
be seen from Table 4, are reported for years one, three 
Figure 1. Probability of DFS for ER Positive (left hand) and ER Negative (right hand) in Low-risk Patients by 
the Tpe of Adjuvant Chemotherapy Regimes
Figure 2. Probability of DFS for ER Positive (left hand) and ER Negative (right hand) in High-risk Patients by 
the Type of Adjuvant Chemotherapy Regimes
Table 4. The Percentage of Different Patients Without Recurrence/Metastasis of Breast Cancer Over Time
   ER positive   ER negative 
 No. of years taxane-based (%) anthracycline- CMF (%) taxane-based (%) anthracycline- CMF (%) 
 following MRM   based (%)   based (%)
low-risk  1 year 99.98 99.72 98.81 95.85 88.50 82.20
patients* 3 years 99.97 99.34 97.29 94.53 85.21 77.56
 5 years 99.72 93.63 77.10 88.39 71.73 60.3
high-risk  1 year 39.35 2.65 0.62 46.26 22.30 14.69
patients† 3 years 21.94 1.167 0.27 39.18 17.68 11.42
 5 years 2.57 0.11 0.03 22.11 8.641 5.37
* < 5cm, Grade I or II tumor and non-involvement of lymph nodes; † > 5cm, Grade III tumor and lymph node involvement
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and five following the surgery. For low risk patients, DFS 
percentage of ER positive patients is higher than that of 
ER negative patients. However, the ER role gradually 
changes over time resulting in higher DFS percentages 
for ER negative patients compared to that of ER positive 
ones. This role reversal occurs 5 years after the surgery 
(Table 4). On the other hand, in high risk patients, while 
DFS percentage of ER positive patients is again higher 
than that of ER negative patients, the inversion of ER role 
occurs before the first year following surgery (Table 4). 
 Figure 1 displays the probability of disease-free 
survival by ER status in low risk patients. The probability 
of disease-free survival dropped down after about three 
years for the ER positive patients treated with CMF. 
Nevertheless, its probability is more than that of ER-
negative patients treated with CMF. The DFS curve for 
women who received taxane-based regimes was slightly 
above the curve for those who received anthracycline-
based regimes in both ER-positive and ER-negative low-
risk patients. The probability of disease-free survival by 
ER status in high risk patients is illustrated in Figure 2. 
The probability of DFS in all chemotherapy arms dropped 
drastically for high-risk patients but not for low-risk 
patients. 
Discussion
 In this study, we compared three common adjuvant 
chemotherapy regimes in terms of DFS, adjusted by 
some factors using an extended log-logistic model 
(Kleinbaum and Klein, 2005). The data were collected 
from three hospitals in Tehran. Adjuvant chemotherapy 
arms were almost homogenous according to a number of 
BC risk factors (age at the time of diagnosis: p = 0.09, 
age of menarche: p = 0.6 and menopause status: p = 0.48) 
although the number of pregnancies were different in the 
three arms (p = 0.01).
 In the model reported in Table 3, the following 
factors play an important role: (i) the type of adjuvant 
therapy regime, (ii) the tumor characteristics at the 
time of diagnosis (tumor size, involvement of lymph 
nodes and histological grade) and (iii) ER status. In 
their study, (Hayes et al., 2007) showed that taxane-
based regime (addition of paclitaxel to doxorubicin plus 
cyclophosphamide) may improve disease-free survival 
compared to anthracycline-based regime (doxorubicin 
plus cyclophosphamide) in HER2 positive patients. 
BIG 02-98 randomized trial study, also, suggested that 
addition of docetaxel into anthracycline-based adjuvant 
chemotherapy results in the improvement of DFS (HR 
= 0.86, p = 0.05) (Francis et al., 2008). In their meta-
analysis that included thirteen studies, (Michele De 
Laurentiis et al., 2008) showed that regardless of the type 
of taxane agent, number of involved lymph nodes, ER 
status, age and menopause status, taxane-based regimes 
were more efficient than anthracycline-based adjuvant 
chemotherapy in terms of DFS (pooled HR= 0.83, p < 
0.001). Similarly, the results we obtained confirmed that, 
compared to anthracycline-based regimes, taxane-based 
regimes improved DFS, but the difference between these 
two types of chemotherapy regimes was not significant 
(OR (anthracycline-based vs. taxane-based) = 0.74, 95% 
CI: 0.23-2.43, p = 0.63). Furthermore, based on the current 
study, taxane-based regime is significantly more effective 
than CMF regime in prolonging DFS (OR (CMF vs. 
taxane-based) = 0.33, 95% CI: 0.11-1.00, p = 0.05). 
 Early detection of BC is a favorable prognosis factor in 
increasing survival time (Shen et al., 2005). In their review 
of  PubMed database from 1995 to 2006, Soerjomataram 
et al. (2008) showed that tumor size, nodal status and 
histological grade remained the strongest prognosis factors 
for long-term survival. Similar results were observed in 
the current study; Table 3 shows that small size of the 
tumor  (p < 0.01), low grade of the tumor (p < 0.01) and 
non-involvement of lymph nodes (p = 0.07) provide a 
better prognosis of DFS. However, probably due to the 
fact that women with larger tumors tend to have more 
positive lymph nodes (Weiss et al., 2003), the lymph 
node involvement was not statistically significant. This 
finding, once more, highlights the conclusion that the early 
detection of BC improves DFS (Table 4). Some studies 
have suggested the early detection of BC can result in an 
almost 30-percent reduction in the mortality rate among 
BC patients (Alexander et al., 1999; Nystrom et al., 2002). 
Bakhtyari A, Hajyan (2007) reported that late detection 
of BC in Iranian women, as compared with its detection 
in women from developed countries, results in a decrease 
in DFS. The results of Lamyian et al., (2007)’s qualitative 
study pointed out that there are some major barriers to 
facilitation of screening for early detection of BC in Iran. 
Early Breast Cancer Trialist Collaborative Group (1992) 
found that the role of ER status on survival probability 
in BC patients is complicated. It is possible that a factor, 
initially, have an effect on the risk of recurrence, yet 
the effect may reverse over time (Dignam et al., 2009; 
Anderson et al., 2006). Some studies reported that 
compared to ER negative patients, ER positive patients 
faced a lower risk in the first several months, but this 
trend inversed afterwards (Hess et al., 2003; Saphner et 
al., 1996). Because of the non-constant hazard ratio of 
ER over time, Dignam et al. (2009) suggested using an 
extended version of Cox hazard model. In order to take 
into account the above-mentioned complication, we used 
an extended model with complex parameters to model the 
effect of ER status. Based on the AIC, our selected model 
fits the data better than a simple one. According to this 
model, ER-positive patients have good prognosis at the 
early stages of treatment with tamoxifen, but the trend 
changes afterwards. Table 4 illustrates that for the low-
risk patients, the change occurs after five years following 
surgery. However, the change in trend happens before the 
first year for high-risk patients. This findings are consistent 
with the results obtained by Dignam et al. (2009).
 In conclusion, this study showed that the type of 
adjuvant chemotherapy regime and tumor characteristics 
have direct effects on DFS. In addition, it was demonstrated 
that the early detection of BC can improve the results of 
treatment. As a result, the role of raising awareness about 
breast cancer, self-examination and screening programs 
is accentuated. Needless to say, considering the limited 
information about adjuvant chemotherapy in Iran, this 
study can also prove to be significant as far as it sheds 
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